Case history {#Sec1}
============

A 24-year male presented with fever, confusion, dysarthria and grand mal seizure. He was recently diagnosed with severe falciparum malaria with multi-organ dysfunction, after being non-compliant with anti-malarial prophylaxis, while working for the Peace Corps in Togo in November 2017. He was treated with IV quinine with complete clearance of his parasitemia. He fully recovered but still required dialysis, and returned to the United States in December 2017. On the day of admission in late December, he arrived for scheduled dialysis and was found to be tachycardic which prompted him to be sent to an outside hospital, where he had an episode of confusion and dysarthria, after which he returned to his baseline mentation. A computed tomography (CT) scan of the head was unremarkable. Next day, the patient had a grand mal seizure. A CT of the head was repeated which was again negative for any acute findings. No focal neurological deficit was observed following the seizure. However, the patient remained lethargic, agitated, and was not speaking or following commands, prompting the transfer to our hospital. On arrival, had a fever of 38.9 °C with sinus tachycardia of 130 beats/min, normal blood pressure and Glasgow Coma Scale (GCS) score of 7. He was lethargic, wincing with sternal rub, not responding to verbal commands, and had no meningismus.

The patient's white count was 15.3 × 10^3^/µL (4--10 × 10^3^/µL), hematocrit of 27.5%, with normal platelets (286 × 10^3^/µL). His creatinine was 2.11 mg/dL, sodium 135 mmol/L, potassium 3.9 mmol/L and serum glucose 97 mg/dL. The total bilirubin and liver enzymes were normal. His human immunodeficiency virus, Epstein--Barr virus, dengue, West Nile virus and Lyme serology were negative, and rapid plasma regain (RPR) was non-reactive. Cerebral fluid (CSF) analysis revealed WBC of 75/µL with 91% lymphocytes, elevated protein of 65 mg/dL and glucose of 64 mg/dL. CSF Gram's and acid-fast bacillus stains were negative. CSF polymerase chain reaction (PCR) pathogen panel (Biofire[1](#Fn1){ref-type="fn"}) for neurotropic bacteria, fungi and viruses was negative. CSF, blood, urine cultures and toxicology screening test were negative as well. CSF VDRL, Cryptococcal antigen and respiratory viral panel (RSV[2](#Fn2){ref-type="fn"}) were negative. Malaria smears were done on admission and the next day, and both were negative.

Chest X-ray, CT head and CT abdomen and thorax were unrevealing. Magnetic resonance imaging (MRI) of the brain revealed nonspecific focus of signal abnormality in the posterior limb of the right internal capsule without evidence of acute infarction in this region.

The patient was started on broad-spectrum antibiotics, acyclovir and Artemether--Lumefantrine, which were subsequently discontinued following negative laboratory results. A clinical diagnosis of PMNS was made and prednisone therapy was started at 1 mg/kg/day. His mentation began improving the next day, and steroids were tapered over 5 days with full recovery. Subsequent follow-up at 3 months revealed normal neurological examination.

Discussion {#Sec2}
==========

There are several neurological syndromes that can occur following complete recovery from malaria, in particular *Plasmodium falciparum*. These syndromes include PMNS, delayed cerebellar ataxia (DCA), acute inflammatory demyelinating polyneuropathy (AIDP) and acute disseminated encephalomyelitis (ADEM) \[[@CR1]--[@CR3]\]. PMNS shares many characteristics of ADEM; hence, some authors describe PMNS as a form of ADEM.

PMNS is a predominantly self-limited condition, which can occur following severe falciparum malaria, not necessarily cerebral \[[@CR1], [@CR3]\]. Schnorf et al. \[[@CR4]\] classified the syndrome into three categories based on clinical severity: a mild form characterized by isolated cerebellar ataxia or postural tremor; a diffuse, relatively mild encephalopathic form, associated with acute confusion or seizures; and a severe encephalopathy typified by motor aphasia, generalized myoclonus, postural tremor, and cerebellar ataxia.

The incidence of PMNS in patients after falciparum malaria can range from 0.7 to 1.8 per 1000 and it is 300 times more common in patients with severe rather than uncomplicated malaria \[[@CR1]\]. The diagnosis of PMNS requires both proven symptomatic malaria infection with full initial clinical recovery and clearance of parasitemia following treatment, and the development of neurological or psychiatric symptoms within 2 months of acute illness \[[@CR1]\].

We searched PMNS-related articles using PubMed and Google search engines and a total of forty nine cases, including our case, met the diagnostic criteria (Table [1](#Tab1){ref-type="table"}). 24 (49%) infections were contracted in Asia, 24 (49%) in Africa, and 1(2%) in the Dominican Republic. Although most cases of *P. falciparum* occur in Africa, our results appear to be skewed by the large Vietnamese study \[[@CR1]\]. There were 36 males and 13 females with male:female ratio of around 2.76:1. All the cases were preceded by falciparum malaria except one, which had *P. vivax*, reported from India. PMNS occurred mostly in patients who had preceding severe falciparum malaria. The mean parasitemia was 19.4% for 22 cases in which it was quantified. The common clinical features were confusion (50%), fever (47.7%), seizure (31.8%), speech abnormalities (18.2%), tremor (18.2%), behavioral abnormities (16%), impaired consciousness (16%), myoclonus (11.3%), ataxia (11.3%) and headache (6.8%). Less common features were psychosis (6.8%), catatonia (4.5%), hallucinations (6.8%), weakness (4.5%), dizziness (4.5%), mydriasis (4.5%), nystagmus (2.2%), paraplegia (2.2%), and somnolence (2.2%). The median duration of onset of PMNS in Nguyen's study of 22 patients was 4 days; in 22 patients (out of 27 that these data were available for) the median duration was 14 days. However, the syndrome can occur anywhere from 0 to 60 days following clearance of parasitemia \[[@CR1]\]. The median duration of symptoms was 13 days (range 3--25 days) excluding Nguyen's study; in his study, it was 2.5 days (range 1--10).

Table 1Summary of PMNS cases reported in the literatureNo.AuthorLocationAge (year)/sex*P. falciparum* parasitemia (%)Onset of PMNS (days)Signs and symptomsAnti-malarial treatmentLaboratory findings during PMNSSteroid usePMNS duration and clinical evolutionCSFMRI/CT1--22Nguyen et al. \[[@CR1]\]VietnamMean age 29M---15F---7NAMedian 4Range0--60Fever (9), acute confusion (15) generalized seizures (8), fine tremor (1) catatonia with waxy flexibility (2) psychosis (3)Artemisinins (13), quinine (10), s/p (4), Mefloquine (17)Elevated O.P. 1/22 WBC 8--80 8/22 lymphocyte predominance 8/8; elevated protein 13/22NoMedian = 2.5 (range 1--10)23Schnorf et al. \[[@CR4]\]Africa 199834/F45%17Tremor, word-finding difficulty, expressive aphasia, mild cerebellar ataxia, tonic--clonic seizures, fever, myoclonusQuinine, clindamycinWBC 10/uL, 95% lymphs; protein 0.6 g/LAbnormal/normalIV MP 100 mg × 3 days with tapering for 10 daysFast improvement after 24 h of initiation of steroid. All the symptoms resolved by 10 days except postural tremor of arms24Schnorf et al. \[[@CR4]\]Cameroon 199861/M50%16Word-finding difficulty, expressive aphasia headache, irritability myoclonus, tremor, fever, ataxiaQuinine, doxycycline, MefloquineWBC 80/uL, 87% lymphs, 12% mono; protein 1.8 g/LNormal/normalPrednisone 60 mg for 4 daysRapid improvement of all symptoms after 24 h of initiation of steroid. All symptoms resolved by 13 days with residual postural tremor of arms25Mohsen et al. \[[@CR3]\]Kenya 200030/F29%35Confusion, lethargy, language difficulties prosopagnosia, seizure, odd behaviorQuinine doxycycline22 lymphs/uL protein 1.4 g/LAbnormal/normalNoGradual improvement of symptoms over a week and recover to normal in 14 days26Lawn et al. \[[@CR7]\]Gambia 200244/M32%14Fever, incoherent speech, confusionUncooperative behavior, acalculia, GCS 12Quinine, S/P4 lymphs/uL protein 0.89 g/LNormal/normalNoSteady improvement of confusional state over a week. The total PMNS duration was 15 days27Lawn et al. \[[@CR5]\]Gambia 200222/F22%7B/L UE and LE postural tremor nominal aphasia feverQuinine, S/P59 lymphs/uL protein 2.59 g/LNormal/normalPrednisone 60 mg/day with tapering over 10 daysRapid diminution of all symptoms after initiation of steroid. All symptoms resolved by 5 days of treatment. PMNS duration was 17 days28Falchook et al. \[[@CR6]\]Ghana 200350/F0.2%11AMA, GCS 10, UE and LE myoclonus jerking, tremors visual/auditory hallucinations expressive aphasiaQuinine, doxycycline, malarone3WBC/uL protein 0.31 g/LAbnormal/normalNo10 days after the onset of symptoms, her mental status began to improve and all neurological symptoms resolved over 2 days. PMNS duration was 12days29Hsieh et al. \[[@CR7]\]Malawi 200350/MNA14Dizziness, headache, horizontal diplopia, mild hand tremor, unsteady gait and easy fallingAugmentin, Cipro, clindamycin, ceftriaxone, artesunate, doxy, quinine, MefloquineWBC-0/mL3 ; glucose, 50 mg/dL; protein, 205 mg/dLNormal/NAIV MP 80 mg/day × 3 days f/b PO prednisone 45 mg/day × 6 daysUnsteady gait persisted for 2 wks until initiation of steroids which gradually improved. He absconded on the 9th day of steroids t/t with clear consciousness and ambulation30Palmieri et al. \[[@CR8]\]Mozambique 200442/M\> 10%14Nominal aphasia, fine tremor (intention) fever, confusion, GCS 12 inappropriate speech, disturbed behaviorQuinine45 lymphs/uL protein 1.29 g/LNormal/normalNoNeurological symptoms improved steadily over a week. No residual neurological sequelae. PMNS duration was 9 days31Zambito et al. \[[@CR9]\]French Guinea 200460/M0.02%9Generalized weakness disorientation tremor, dizzinessQuinine, doxy, ceftriaxone20 lymphs/uL protein 2.52 g/LNormal/normalNoSymptoms resolved spontaneously over 3 days32Silva-pinto et al. \[[@CR10]\]Angola 200438/M70%11Headache, behavior impairment, ataxic gait, consciousness impairment/AMAQuinine/doxycycline75 mononuclear protein 1.14 g/L glucose (%, CSF/Serum) 60Abnormal/NAIV MP 1 g/day × 3daysGradual improvement, recovery to normal status in 10 months33van der Wal et al. \[[@CR11]\]Kenya 200553/M6%17Mixed aphasia, confusion, position tremor, mydriasis, generalized, restlessness, fever word-finding, difficultyQuinine, ciprofloxacin, cefazolinWBC 5/uL, 24% lymphs; protein 0.67 g/LNA/normalPrednisone 75 mg × 3 days then tapered with 10 mg/dayRapid recovery seen within 24 h of initiating steroid. PMNS duration was 12 days34Mizuno et al. \[[@CR12]\]West Africa 200554/M10%21Incoherent speech acute confusion fever, uncooperative behaviorMefloquine, artemisinin10 lymphs/uL protein 0.83 g/LNormal/normalNoAcute confusional state improved steadily over a week and full recovery without sequelae by 13th day35Prendki et al. \[[@CR13]\]Ivory Coast 200619/M2.5%57Dizziness, mood disorders, generalized seizures, fever, GCS 6Quinine76 WBC/uL 100% lymphs protein 0.52 g/LNormal/normalNoImproved gradually over 14 days with no neurological sequelae36Prendki et al. \[[@CR13]\]Gambia 200617/M9%14Fever, confusion, clouded consciousness/AMA, generalized seizureQuinine26 WBC/uL, 91% lymphs; protein 1.88 g/LNormal/normalNoImproved gradually over 12 days with no neurological sequelae37Markley et al. \[[@CR14]\]Dominican Republic 200743/M23%18Headache, tremor word-finding difficulty, disorientation, inattention, acalculia, agraphesthesia, conductive aphasia, perseverationMefloquine, quinine, doxycycline, A/P20 lymphs/uL protein 0.92 g/LNormal/normalPrednisone 60 mg/day with tapered over 1 weekImproved dramatically over 3 days after initiation of steroid and all symptoms resolved by 5th day except a mild tremor. 21 days38Matias et al. \[[@CR15]\]India 200861/M50%2Delirium, somnolence dysarthria, dysphagia cerebellar ataxia nystagmus, palatal palsyQuinine, doxycycline4WBC/uL protein 1.38 g/LAbnormal/normalMethylprednisolone 1 g/day × 3daysSignificant improvement of neurological deficits with steroid. All symptoms resolved except mild dysarthria and ataxia by 25th day. Normal NE by 9 months39Odawara et al. \[[@CR16]\]Sierra Leone, 200956/M4.8%17Fever, ataxia, tremor, confusionMefloquine/artesunate19 WBC, protein 1.43 g/LNormal/NANoGradually improved without specific treatment and without residual symptoms in 20 days40Rakotoarivelo et al. \[[@CR17]\]Madagscan16/M0.87%9Confusion and tremor, ataxia, seizureQuinine, artesunate and amodiaquine31 WBC with 98% lymphocytes, 2 g/L proteinNoResolution of all neurological symptoms in 10 days41Pace et al. \[[@CR18]\]Sierra Leone 201148/F*NR*10Nystagmus, minimal neck and shoulder muscle weakness with hyperreflexia, flaccid paraplegia with retained reflexes, urinary retention, reduced anal tone and a sensory lossArtesunate and amodiaquineNPAbnormal/NAMP × 3 daysNeurological deficit began improving within 36 h of steroid with minimal paraparesis by 2 weeks. 14 days42Mittal et al. \[[@CR19]\]India 201560/Mplasmodium vivax7Seizure, cognitive dysfunction tremors, mild aphasia and inappropriate response to command, weaknessNANPAbnormal/NANo43Silva-pinto et al. \[[@CR10]\]Ivory coast, 201645/M25%11Fever, behavior impairment, myoclonus, visual hallucination, decrease consciousness/AMA, working memory deficitQuinine/doxycycline99 monocyte, 2.09 g/L, glucose (%, CSF/Serum) 70Normal/NANoGradual improvement with mild cognitive dysfunction after 6 months44Costa et al. \[[@CR20]\]Angola, 201657/M8%11Fever, behavior impairment, myoclonus, circadian rhythm disturbance, working memory deficit, visual construction inabilityQuinine/doxycycline159 monocyte, 2.12 g/L, glucose (%CSF/serum)60Abnormal/NAMP 5daysFast improvement persistence of slight attention deficit45O'Brien et al. \[[@CR2]\]West Africa, 201642/M5.6%30Confusion, disorientation, memory and communication difficultiesQuinine/doxycyclineNPAbnormal/NAMP × 3 days followed by prednisone 60 mg, tapering over 6 weeksSlowly improved clinically and after 16 days had significant improvement except some cognitive, memory and communication problem. All symptoms completely resolved by 5--6 months46Chiabi et al. \[[@CR21]\]Cameroon7/FNR1Visual hallucinations, confusion, incomprehensible words, behavioral impairmentArtesunateNPNPNoSymptoms started regressing after 48 h and all symptoms resolved by day 347Siriez et al. \[[@CR22]\]Mali, 201714/M*9%*10Impaired consciousness/AMA, mydriasisQuinine, A/P35 WBC with 100%monocytes, protein 1.22 g/LNormal/normalNoNeurological signs resolved fully within 48 h48Almuntaser et al. \[[@CR23]\]Africa15/M*NR*42Seizure, raised ICPNA16 wbc, 1.38 g/LAbnormal/NAYesFull recovery with no neurological deficit by day 649Togo 201724/M*14%*30Seizure, fever, lethargy, dysarthria, impaired consciousnessQuinineWBC---75/µL with 91% lymphs, RBC---65/µL, protein--- 65 mg/dL, glucose---64 mg/dLAbnormal/normalPrednisone 80 mg/day with tapering over 5 daysMentation began improving on the second day of the initiation of steroid, and he fully recovered by day five of therapy*AMA* altered mental status, *A*/*P* atovaquone/proguanil, *CT scan* computed tomography scan, *F* female, *M* male, *MRI* magnetic resonance imaging, *MP* methylprednisolone, *NE* neurological examination, *NR* not recorded, *NA* not available, *S/P* sulfadoxine/pyrimethamine

The exact pathogenesis of PMNS is not known. Some authors suggest obstruction of cerebral microvasculature by parasitized red blood cell inducing cerebral hypoxemia \[[@CR1], [@CR7]\]. Hsieh et al. \[[@CR7]\] described brain single-photon emission computed tomography (SPECT) findings with markedly decreased radioactivity. However, this mechanism is questionable as obstruction of microvasculature does not seem plausible due to the potentially long delay between malaria episode and PMNS. Another postulated hypothesis is immune mediated based on a positive response to corticosteroid therapy in some patients, and lagging of onset of PMNS symptoms after resolution of malaria symptoms \[[@CR4]\]. An increment of serum and CSF concentrations of inflammatory cytokines such as TNF-alpha, IL 2 and IL 6 has been described in some cases of delayed post-malaria cerebellar syndrome, which decreased following steroid therapy \[[@CR24]\]. There is also some evidence of possible molecular mimicry, whereby antibodies to antigens expressed by certain strains of *P. falciparum* cross-react with antigens in the CNS \[[@CR5]\]. However, a study by Siriez et al. \[[@CR22]\] was unable to detect intrathecal IgG and specific *P. falciparum* antibodies in the CSF. Coinfection or reactivation of a viral infection capable of causing encephalitis has been suggested as another possible mechanism \[[@CR4]\]. Schnorf et al. found elevated IgG and IgM antibodies against CMV and EBV in the serum but not the CSF of one of his patients, and positive IgG antibody against varicella zoster virus in the CSF and serum of the same patient albeit PCR repeatedly failed to detect genetic material of EBV, CMV, and VZV in the CSF. In fact, *P. falciparum* infection has been shown to induce polyclonal B cell activation and subsequent secretion of different antibodies, causing false-positive serological tests \[[@CR25], [@CR26]\]. Nguyen et al. implicated Mefloquine as a possible cause of PMNS since 17 of 22 patients (77%) were treated with Mefloquine. However, altogether 25 of 46 PMNS cases (54.3%) in our review were not taking Mefloquine.

CSF findings in PMS may be variable and may show risen opening pressure, pleocytosis and elevated protein. CSF analysis was performed in all cases except two, which revealed lymphocytic pleocytosis in two-thirds of the patients with an elevated protein in one-third.

MRI brain can be unremarkable or reveal some signal changes in various parts of brain. 10 out of 23 cases had abnormal MRI of brain. The abnormalities consisted of nonspecific findings with increased signal uptake in various regions of brain, including the periventricular areas, brain stem, thalamus, corona radiata, internal capsule, and cerebellum. In one case, there was inflammation of spinal cord along with brain stem and cerebellar peduncles while another patient had evidence of optic neuritis with cerebral edema \[[@CR18], [@CR23]\]. CT scans were normal in all cases in which MRI was abnormal.

PMNS usually does not require specific treatment. However, in severe cases steroids may help to hasten recovery \[[@CR4], [@CR7], [@CR14]\]. Schnorf et al. observed two patients that continued to have worsening neurological symptoms until steroids were initiated, with rapid recovery \[[@CR4]\]. Similarly, Hsieh et al. described persistent unsteadiness in their patient with PMNS for 2 weeks until the use of corticosteroids, which resulted in dramatic recovery. Overall in our literature review, 12 out of 48 were treated with steroids and all had rapid recovery within a few days of initiation of steroid therapy except two patients in which recovery was gradual. About half of the patients received oral prednisone initiated at 1 mg/kg/day and tapered over 7--10 days while most of the remaining patients received IV methyl prednisolone for 3--5 days. The neurological signs and symptoms of PMNS in most of patients resolved within days to weeks.

In conclusion, PMNS is a rare complication of severe malaria that might be underreported. It can develop up to 2 months after clearance of parasitemia. Clinical features can be variable. Most cases are self-limited but more severe cases may benefit from steroid therapy. In patients with recent history of malaria that present with neuropsychiatric symptoms, PMNS should be strongly considered.

CSF pathology panel (Biofire) includes *E. coli* K1, *H. influenza, Listeria monocytogenes, N. meningitides, Streptococcus agalactiae, Streptococcus pneumoniae, Cytomegalovirus, Enterovirus*, herpes simplex viruses 1 and 2, human herpes virus 6, human *Parechovirus*, varicella zoster virus, *Cryptococcus neoformans*/*gattii*.

Repiratory viral panel (RVP) influenza A & B viruses, respiratory syncytial virus, *Human metapneumovirus*, parainfluenza virus 1--4, adenovirus, rhinovirus/*Enterovirus, Coronavirus* HKU1, NL63, OC43, and 229E, *Bordetella pertussis, Mycoplasma pneumoniae* and *Chlymadia pneumoniae*.

The authors declare that they have no competing interests.
